Table 5.
MIC (μg/mL) values for the tick-derived C.davisae isolate as defined with the microdilution method Interpretation is based on clinical breakpoints defined by EUCAST (http://www.eucast.org/clinical_breakpoints accessed on 1 January 2021) or ECOFF (indicated by asterisks). Int. stands for interpretation, R. for resistant and S. for sensitive.
| Antibiotic Class | Antibiotic Abbreviation | Antibiotic | Cedecea davisae (Tick) | Escherichia coli ATCC 25922 | Enterobacterales (EUCAST Clinical Breakpoints 1 January 2021) and ECOFF (*) | |||
|---|---|---|---|---|---|---|---|---|
| MIC (µg/mL) | Int. | MIC (µg/mL) | Int. | S≤ | R> | |||
| Aminoglycosides | GEN | Gentamicin | ≤0.5 | S | ≤0.5 | S | 2 | 2 |
| STR | Streptomycin | ≤4 | S * | >16 * | ||||
| Carbapenem | MERO | Meropenem | 0.12 | S | ≤0.03 | S | 2 | 8 |
| Cephalosporins | FOT | Cefotaxime | ≤0.25 | S | ≤0.25 | S | 1 | 2 |
| FOX | Cefoxitin | >16 | R * | 8 * | 8 * | |||
| TAZ | Ceftazidime | ≤0.5 | S | ≤0.5 | S | 1 | 4 | |
| Diterpenes | TIA | Tiamulin | >4 | |||||
| Fluoroquinolones | CIP | Ciprofloxacin | ≤0.015 | S | ≤0.015 | S | 0.25 | 0.5 |
| NAL | Nalidixic Acid | ≤4 | S * | ≤4 | S * | >8 | ||
| Macrolides, lincosamides and streptogramins | AZI | Azithromycin | 16 | 4 | ||||
| Penicillins | AMP | Ampicillin | >64 | R | 4 | S | 8 | 8 |
| Tetracyclines | TET | Tetracycline | ≤2 | S * | ≤2 | S * | >8 * | |
| TGC | Tigecycline | ≤0.25 | S * | ≤0.25 | S * | 1 | >0.5 | |
| Miscellaneous agent | CHL | Chloramphenicol | ≤8 | S | ≤8 | S | 8 | 8 |
| COL | Colistin | >16 | R | ≤1 | S | 2 | 2 | |
| KAN | Kanamycin | ≤4 | ||||||
| MUP | Mupirocin | 256 | ||||||
| RIF | Rifampicin | >0.5 | ||||||
| SMX | Sulfamethoxazole | >1024 | 64 | |||||
| TMP | Trimethoprim | ≤0.25 | S | 0.5 | S | 4 | 4 | |
* when no clinical breakpoints available, interpretation was based on epidemiological cutoffs (ECOFF) values.